@chelseygobbo's TRT for women claims, fact-checked

What did @chelseygobbo actually say?

A nurse and self-described over-40 mom documented her first six weeks on injectable testosterone, sharing that her OBGYN dismissed her symptoms two years ago as "pretty much okay." She describes fatigue, brain fog, mood swings, and insomnia as her driving complaints, and credits a hormone specialist with finally running comprehensive labs. She also claims that being "low normal" on labs is not the same as being "optimal," and that pellets are harder to dose-adjust than injections.

She is not making dramatic cure claims. She is sharing a personal experience, being careful to say the side effects (back acne, skin breakouts) are "not intolerable," and encouraging women to seek second opinions rather than accept dismissal from primary care providers.

Does the science back this up?

Largely yes, though with important caveats. Testosterone does play a role in women's energy, mood, libido, and cognitive function, and its levels do decline with age. But the clinical picture is messier than most TikTok videos let on.

A 2019 consensus statement from the Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davison et al., Journal of Clinical Endocrinology and Metabolism) concluded that testosterone therapy in women has reasonable evidence for improving sexual function, but the evidence for fatigue, brain fog, and sleep specifically is much weaker and more mixed. The "low normal vs. optimal" framing she uses is genuinely debated in endocrinology. There is no universally agreed-upon "optimal" range for testosterone in women, and the concept is frequently used by hormone optimization clinics in ways that outpace the evidence. That does not make her experience invalid, but it does mean the framing is doing more clinical work than the data supports.

Her observation that acne appeared around weeks four to five is consistent with known androgenic side effects of testosterone therapy documented in the literature (Davis et al., 2019, Lancet Diabetes and Endocrinology).

What did they get wrong (or right)?

She got the delivery method comparison mostly right. Pellet dosing is genuinely less adjustable than injections. Once a pellet is implanted, you cannot reduce the dose if side effects emerge. A 2021 review in Maturitas (Glaser and Dimitrakakis) acknowledged this limitation directly, noting that pellet therapy lacks the titration flexibility of other methods. That is a real clinical consideration, not just a preference.

Where she is on shakier ground is the blanket suggestion that primary care physicians and OBGYNs routinely fail women on hormone health. Some do dismiss symptoms too quickly, and that is a real and documented problem. But she is also describing a system where a hormone optimization clinic, which has a financial incentive to treat, told her she needed treatment. That conflict of interest is worth naming. The "normal but not optimal" framing is a common upsell in the hormone clinic world, and patients deserve to know that before signing up.

She is right that injectable testosterone allows tighter dose control. She is wrong to imply pellets are simply a needle-free alternative with equivalent flexibility. They are not equivalent in that specific way.

What should you actually know?

If you are a perimenopausal woman experiencing fatigue, mood changes, and sleep disruption, testosterone is one piece of a complex hormonal picture that also includes estrogen, progesterone, cortisol, and thyroid function. Starting with testosterone alone, without ruling out those other factors, is common at hormone clinics but is not necessarily the most evidence-based first step.

The FDA has not approved any testosterone product specifically for use in women in the United States. Women who use testosterone are doing so off-label, which is legal and sometimes clinically appropriate, but it means long-term safety data in women is thinner than it is for men. The 2019 Global Consensus Statement did call for more research specifically because that gap exists.

Six weeks is also a very short window. Many of the subjective benefits she is describing, increased energy in week two, are consistent with a placebo response, which is strong and real in hormone studies. That does not mean the treatment is not working. It means six weeks is not enough time to know.

If your provider dismissed your symptoms without running labs, getting a second opinion is reasonable. But seek that opinion from a board-certified reproductive endocrinologist or a menopause specialist certified by the Menopause Society, not just from any clinic advertising hormone optimization.